FRONTLINE TRI-ACT 67.6 MG / 504.8 MG SPOT-ON SOLUTION FOR DOGS 5-10 KG

Authorised

- Fipronil
- Permethrin

Product identification

Medicine name:
FRONTLINE TRI-ACT 67.6 MG / 504.8 MG SPOT-ON SOLUTION FOR DOGS 5-10 KG
Frontline Tri-Act 67,6 mg / 504,8 mg διάλυμα για επίχυση σε σημείο (spot-on) για σκύλους 5-10 kg

Active substance:
Fipronil

Permethrin

Target species:
Dog

Route of administration:
Cutaneous use

Product details

Active substance and strength:
Fipronil

67.60 milligram(s) / 1.00 millilitre(s)

Permethrin
504.80 milligram(s) / 1.00 millilitre(s)

Pharmaceutical form:
Spot-on solution

Withdrawal period by route of administration:
Cutaneous use:

- **Dog**

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QP53AX65

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
Cyprus

Package description:
Plastic card of 1 pipette containing 1 ml
Carton box of 6 pipettes containing 1 ml each
Carton box of 3 pipettes containing 1 ml each

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Fixed combination application (Article 13b of Directive No 2001/82/EC)

Marketing authorisation holder:

Boehringer Ingelheim Animal Health France

Marketing authorisation date:
30/07/2014

Manufacturing sites for batch release:
Boehringer Ingelheim Animal Health France

Responsible authority:
Veterinary Services, Ministry Of Agriculture, Natural Resources And Environment

Authorisation number:
CY00461V

Date of authorisation status change:
23/05/2019

Reference member state:
France

Procedure number:
FR/V/0266/002

Concerned member states:
Austria Belgium Bulgaria Croatia Cyprus Czechia Estonia Germany Greece Hungary Italy Latvia Lithuania Luxembourg Malta Netherlands Poland Portugal Romania Slovakia Slovenia Spain United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Combined File of all Documents

This document does not exist in this language (English). You can find it in another language below.
